

CV Date	24/04/2023
---------	------------

Part A. PERSONAL INFORMATION

First Name *	REGINA		
Family Name *	ALEMANY ALONSO		
Sex *	Female	Date of Birth *	23/02/1969
ID number Social Security, Passport *	43051882E	Phone Number *	(34) 971259619
URL Web			
Email Address	regina.alemany@uib.es		
Researcher's identification number	Open Researcher and Contributor ID (ORCID) *	0000-0003-2180-1213	
	Researcher ID	A-2314-2011	
	Scopus Author ID		

* Mandatory

A.1. Current position

Job Title	Full Professor		
Starting date	2019		
Institution	University of the Balearic Islands		
Department / Centre	Biology / Science		
Country	Spain	Phone Number	
Keywords			

A.2. Previous positions

Period	Job Title / Name of Employer / Country
2011 - 2019	Senior Lecturer / University of the Balearic Islands / Spain
2006 - 2011	Contract Lecturer with a PhD associated to I3 programme / University of the Balearic Islands
2002 - 2006	Researcher of the Ramón y Cajal programme / University of the Balearic Islands
2001 - 2006	Associated Lecturer / Universidad de las Islas Baleares
2000 - 2001	Postdoctoral Researcher at the University of the Balearic Islands / Ministerio de ciencia y tecnología
1999 - 2000	Postdoctoral Researcher / Universitätsklinikum Essen
1997 - 1998	Postdoctoral fellow from the Ministry of Education and Culture / Universitätsklinikum Essen
1996 - 1996	Postdoctoral Researcher / Novartis LTD (antes Sandoz Pharma)
1993 - 1995	Pre-doctoral Researcher / University of the Balearic Islands

A.3. Education

Degree/Master/PhD	University / Country	Year
PhD in Biology	University of the Balearic Islands	1995
Graduate in Biology	University of the Balearic Islands	1993

A.4. General quality indicators of scientific production

Until now I have participated in 28 projects, being the principal investigator in 6. I have published 43 international publications (in 18 of which I am the first or last author or the corresponding author). Number of publications in the first quartile (Q1) = 33 (of which 11 are in the first decile). Average value of the impact index of the publications = 4.85. Sum of citations = 1676 and H-Index = 25 (09 November 2022; Publons). In 2006 I obtained a positive evaluation from the National Evaluation Commission for Research Activity (CNEAI "Comisión

Nacional Evaluadora de la Actividad Investigadora"), which certified having satisfied the quality requirements of production and scientific activity that imply an outstanding research career for the purposes of the I3 programme. I have been supervised 5 doctoral theses; 3 research reports to obtain an Advanced Studies Diploma, 9 master's theses (2011-2022), 8 Bachelor's Thesis (2014-2021), and I am actively participating in the training of future researchers. The National Commission for the Evaluation of Research Activity (CNEAI), which evaluates the quality of the scientific career, has recognized 4 six-year periods (until 2017). I have granted with the remuneration complement of stimulus and recognition for research excellence (from 01/01/2020 to 12/31/2025) and the remuneration complement of stimulus and recognition to research activity (from 01/01/2020 to 12/31/2025), both financed by the Ministry of Education and Science of the Government of the Balearic Islands.

Part B. CV SUMMARY

My interest in Cell Biology, especially in cell signalling, encouraged me after finished my PhD in Biology (1995, University of the Balearic Islands, UIB) to start a postdoctoral training abroad. I worked as postdoctoral researcher for one year (1996) in the "Drug Safety" department of the pharmaceutical company Sandoz Pharma, Ltd (today Novartis) in Basel (Switzerland) and for four years at the Institute of Pharmacology at the University Hospital in Esse (Germany), where I acquired broad expertise in the fields of Molecular Cell Biology and Pharmacology, studying a new cell signalling pathway activated in tumor cells. Then, I started at the UIB at the end of 2000 being funded by a postdoctoral contract (2000-2001) and thereafter by the prestigious Ramón y Cajal programme of Excellence from the Ministry of Science and Technology (2002-2006). My research work from 2001 to 2006, focused on the cellular and molecular mechanisms of a monounsaturated fatty acid derivative, whose pharmaceutical use had been patent by our university (PCT/ES02/00475). My studies were the scientific basis to license its commercial exploitation to two different biotech companies whose aim was to develop it as a drug for the treatment of hypertension or as a chemotherapeutic, respectively. The following positive evaluation for the I3 Programme in 2006 allowed me to promote in my career, first as a Contract Lecturer and finally as Full Professor in Cell Biology. I create the "Clinical and Translational Research Group" at the UIB, which I am currently leading. The researchers of this group also belong to the University Research Institute of Health Science and to the Health Research Institute of the Balearic Islands as members of the "Advanced Therapies and Biomarkers in Clinical Oncology" group. This interdisciplinary group is made up of researchers from the UIB and the Hospital Son Espases (IB-Salut) with specific training in the areas of Molecular Cell Biology, Biochemistry, Pharmacology and Oncology. Our focus is on translational research in the field of soft tissues sarcoma (STS), with an emphasis on the identification of prognostic and predictive biomarkers of response and on understanding of STS oriented to the development of new therapeutic strategies. In the recent past our preclinical studies revealed new cellular-molecular mechanisms involved in the antitumor effect of trabectedin (Eur. J. Pharmacol. 658 (2-3):57-64, 2011) and nilotinib (Plos ONE 7(5):e37735, 2012), which led to clinical trials with patients to evaluate its therapeutic application combined with conventional chemotherapy (J. Clin. Oncol. 34(19):2294-2302 (2016) and Clin. Cancer Res. Oncol. 24(21):5239-5249 (2018)). Likewise, we have demonstrated the relevance of the WNT/b-catenin signalling pathway in sarcomagenesis with CDC25A being a key protein in this process. In this context, we revealed the possibility to regulate this pathway with specific inhibitors, confirming that it can be controlled experimentally with pharmacological drug candidates (Mol. Cancer Ther. 16(6):1166-1176 (2017); Cancers 12:2556 (2020) DOI:10.3390/cancers12092556; Cancers 13:5521 (2021) DOI:10.3390/cancers13215521). I was part of the CIBER network of the Physiopathology of Obesity and Nutrition (2012-2016), and I am also member of the Sarcoma Research Spanish Group (GEIS) since 2008 as well as a registered reviewer for the National Agency of Evaluation and Prospection.

Part C. RELEVANT ACCOMPLISHMENTS

C.1. Publications

AC: corresponding author. (nº x / nº y): position / total authors. If applicable, indicate the number of citations

- 1 **Scientific paper.** Bento, L; Vögler, O; Sas-Barbeito, A; et al; Gutiérrez, A; Alemany, R (AC). (15/16). 2022. Screening for Prognostic microRNAs Associated with Treatment Failure in Diffuse Large B Cell Lymphoma. *Cancers*. MDPI AG. 14-4, pp.1025. ISSN 2072-6694. WOS (1) <https://doi.org/10.3390/cancers14041065>
- 2 **Scientific paper.** Martinez-Font, E; Perez-Capo, M; Vogler, O; Martin-Broto, J; Alemany, R (AC); Obrador-Hevia, A. (5/6). 2021. WNT/beta-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?. *Cancers*. MDPI AG. 13-21, pp.5521. ISSN 2072-6694. WOS (2) <https://doi.org/10.3390/cancers13215521>
- 3 **Scientific paper.** Herraiz, I; Bento, L; Del Campo, R; et al; Gutierrez, A; Alemany, R. (8/11). 2020. Prognostic Role of the Red Blood Cell Distribution Width (RDW) in Hodgkin Lymphoma. *Cancers*. MDPI AG. 12-11, pp.3262. ISSN 2072-6694. WOS (8) <https://doi.org/10.3390/cancers12113262>
- 4 **Scientific paper.** Fernandez-Serra, A; Moura, DS; Sanchez-Izquierdo, MD; et al; Martin-Broto, J; Alemany, R. (12/17). 2020. Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study. *Cancers*. MDPI AG. 12-10, pp.2979. ISSN 2072-6694. WOS (2) <https://doi.org/10.3390/cancers12102979>
- 5 **Scientific paper.** Martinez-Font, E; Perez-Capo, M; Ramos, R; et al; Obrador-Hevia, A; Alemany, R. (10/11). 2020. Impact of Wnt/beta-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas. *Cancers*. MDPI AG. 12-9, pp.2556. ISSN 2072-6694. WOS (7) <https://doi.org/10.3390/cancers12092556>
- 6 **Scientific paper.** Alemany, R; Moura, DS; Redondo, A; et al; Martin-Broto, J. (1/16). 2018. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. *Clinical Cancer Research*. AMER ASSOC CANCER RESEARCH. 24-21, pp.5239-5249. ISSN 1078-0432. WOS (14) <https://doi.org/10.1158/1078-0432.CCR-18-0851>

C.2. Conferences and meetings

- 1 Azparren, L; Nadal-Serrano, M; Pérez, M; Prados, E; Obrador-Hevia, A; Alemany, R; Martinez Font, E. Disruption of the spliceosome activity as a novel therapeutic strategy in soft tissue sarcomas. 18th ASEICA International Congress. ASEICA. 2022. Spain.
- 2 Pérez, M; Nadal-Serrano, M; Martinez-Font, E; et al; Obrador-Hevia, A. Unveiling a new spliceosome-inhibitor drug with antitumor activity on soft tissue sarcoma patient-derived primary cultures. European Association for Cancer Research (EACR) 2022: Innovative Cancer Science: Translating Biology to Medicine. European Association for Cancer Research (EACR). 2022. Spain.
- 3 Bento, L; Ross, T; Muncunill, J; et al; Gutiérrez, A. In vitro validation of micro-RNAs (miRNAs) associated to treatment failure in diffuse large B-cell lymphoma (DLBCL). 62th ASH American Association of Hematology Annual Meeting. 2020. United States of America.
- 4 Bento, L; Ros, T; Muncunill, J; et al; Gutiérrez, A. Analysis of Micro-RNAs Associated to Treatment Failure in Diffuse Large B Cell Lymphoma. 61st American Society of Hematology Annual Meeting. 2019. Participatory - others. Conference.
- 5 Martinez-Font, E; González del Alba, A; Asensio, VJ; et al; Obrador-Hevia, A. Impact of MIR-205-5P and MIR-425-5P on WNT and AR signalling pathways in castration resistant prostate cancer transition. 25th Biennial Congress of the European Association for Cancer Research. 2108. Holland. 'Participatory - poster. Conference.

C.3. Research projects and contracts

- 1 **Project.** GEIS19/01, Análisis genómico exhaustivo de alteraciones accionables de la vía Wnt y validación de dianas terapéuticas en modelos celulares y organoides para evaluación de nuevas terapias en sarcomas de partes blandas. Fundación Mari Paz Jimenez Casado; Grupo Español de Investigación en Sarcomas (GEIS). (Servei de Salut de les Illes Balears/IdISBa). 07/11/2019-06/11/2022. 75.000 €. Team member.

- 2 **Project.** GEIS18/01, SARCOMAS DE PARTES BLANDAS: Nuevos biomarcadores de la vía de Wnt y evaluación de nuevas terapias en modelos celulares y organoides. Grupo Español de Investigación en Sarcomas (GEIS). (Servei de Salut de les Illes Balears/IdISBa). 06/11/2018-05/11/2020. 15.000 €. Team member.
- 3 **Project.** SYN17/04, PROGRAMA SYNERGIA Papel pronóstico y etiopatogénico de la actividad epigenética mediada por miRNAs en el linfoma difuso de célula grande B tratado con R-CHOP con o sin radioterapia. Servei de Salut de les Illes Balears/IdISBa. (Servei de Salut de les Illes Balears/IdISBa). 01/01/2018-31/12/2019. 41.700 €. Principal investigator.